FCMI
Foresite Capital Management II Portfolio holdings
AUM
$29.2M
This Quarter Return
+37.75%
1 Year Return
+44.84%
3 Year Return
-66.21%
5 Year Return
-37.37%
10 Year Return
–
AUM
$460M
AUM Growth
+$460M
(-9.7%)
Cap. Flow
-$241M
Cap. Flow
% of AUM
-52.4%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
1
Reduced
1
Closed
–
Top Buys
| 1 |
Novavax
NVAX
|
$7.3M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$1.25M |
Top Sells
| 1 |
10x Genomics
TXG
|
$249M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
10x Genomics
TXG
$1.74B
| $437M | 95.05% | 3,503,528 -2,000,000 | -36% | -$249M |
|
|
EPZM
2
DELISTED
Epizyme, Inc
EPZM
| $10.3M | 2.24% | 862,402 | – | – |
|
|
3
Novavax
NVAX
$1.21B
| $7.3M | 1.59% | +67,373 | New | +$7.3M |
|
|
XLRN
4
DELISTED
Acceleron Pharma Inc.
XLRN
| $5.16M | 1.12% | 45,884 +11,100 | +32% | +$1.25M |
|